

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI445971

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	SECURITY INTEREST	
CONVEYING PARTY DATA		
Name		Execution Date
Epic Sciences, Inc.		06/26/2024
RECEIVING PARTY DATA		
Company Name:	Laboratory Corporation of America Holdings	
Street Address:	531 South Spring St.	
City:	Burlington	
State/Country:	NORTH CAROLINA	
Postal Code:	27215	
PROPERTY NUMBERS Total: 85		
Property Type	Number	
Application Number:	61540323	
Application Number:	61435721	
Application Number:	61435704	
Application Number:	61435724	
Application Number:	14001154	
Application Number:	61872411	
Application Number:	61934600	
Application Number:	15115225	
Application Number:	61943192	
Application Number:	61932096	
Application Number:	61913722	
Application Number:	15103027	
Application Number:	61921694	
Application Number:	14581968	
Application Number:	61991088	
Application Number:	15309412	
Application Number:	61932117	
Application Number:	61932153	
Application Number:	61932172	
Application Number:	14605809	

PATENT

Property Type	Number
Application Number:	61932597
Application Number:	61932676
Application Number:	61933771
Application Number:	14605913
Application Number:	61933774
Application Number:	14609356
Application Number:	61954445
Application Number:	61253787
Application Number:	13503014
Application Number:	13897136
Application Number:	13393177
Application Number:	14363290
Application Number:	62064320
Application Number:	15519129
Application Number:	15024483
Application Number:	62055491
Application Number:	15513915
Application Number:	14678415
Application Number:	62168607
Application Number:	15577307
Application Number:	62233206
Application Number:	15762076
Application Number:	62250422
Application Number:	15773154
Application Number:	62275659
Application Number:	62344703
Application Number:	16068348
Application Number:	15478002
Application Number:	15601696
Application Number:	62514642
Application Number:	62531725
Application Number:	16617423
Application Number:	15710102
Application Number:	16691461
Application Number:	16819684
Application Number:	16885028
Application Number:	16884737
Application Number:	16992232

Property Type	Number
Application Number:	17142767
Application Number:	17160171
Application Number:	17142662
Application Number:	17170769
Application Number:	17323912
Application Number:	17323976
Application Number:	17377074
Application Number:	17398846
Application Number:	17579437
Application Number:	17700146
Application Number:	17746756
Application Number:	18048759
Application Number:	18175427
Application Number:	18174015
Application Number:	18308579
Application Number:	18495585
Application Number:	18596314
Application Number:	18676257
Application Number:	18076945
Application Number:	15789768
Application Number:	16721108
Application Number:	14374083
Patent Number:	10545151
Patent Number:	10527624
Patent Number:	8445225
Patent Number:	10613089
Patent Number:	11340228

CORRESPONDENCE DATA

Fax Number: 2024033557

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2028241419

Email: klawson@ktslaw.com

Correspondent Name: Kristin M. Lawson

Address Line 1: Kilpatrick Townsend & Stockton LLP

Address Line 2: 701 Pennsylvania Avenue, NW, Suite 200

Address Line 4: Washington, DISTRICT OF COLUMBIA 20004

ATTORNEY DOCKET NUMBER:	057618-1450667
--------------------------------	----------------

NAME OF SUBMITTER:	Kristin Lawson
SIGNATURE:	Kristin Lawson
DATE SIGNED:	08/22/2024
Total Attachments: 18 source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page1.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page2.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page3.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page4.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page5.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page6.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page7.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page8.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page9.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page10.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page11.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page12.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page13.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page14.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page15.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page16.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page17.tiff source=Labcorp Epic Sciences - IP Security Agreement Execution Version#page18.tiff	

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **INTELLECTUAL PROPERTY SECURITY AGREEMENT** (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “IP Security Agreement”), dated as of June 26, 2024, is made by and between Epic Sciences, Inc., a Delaware corporation (the “Grantor”) and Laboratory Corporation of America Holdings (the “Noteholder”).

WHEREAS, the Grantor has entered into that certain Secured Convertible Note Purchase Agreement, dated on or about the date hereof, with the Noteholder (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Note Purchase Agreement”);

WHEREAS, in connection with the Note Purchase Agreement, the Grantor has entered into that certain Secured Promissory Note, dated on or about the date hereof, with the Noteholder (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Note”) and that certain Security Agreement, dated on or about the date hereof, with the Noteholder (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement” and, collectively with the Note Purchase Agreement and the Note, the “Loan Documents”) (capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Security Agreement); and

WHEREAS, under the terms of the Security Agreement, the Grantor has granted to the Noteholder a security interest in, among other property, certain intellectual property of the Grantor, and has agreed thereunder to execute this IP Security Agreement for recording with the U.S. Patent and Trademark Office (the “USPTO”) and/or the U.S. Copyright Office (the “USCO”), as applicable.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees as follows:

Section 1. Grant of Security. The Grantor hereby collaterally assigns and pledges to the Noteholder (and its successors and permitted assigns), a security interest in and to all of the Grantor’s rights, titles and interests in and to the following, whether now owned or hereafter acquired by the Grantor (the “Collateral”):

(i) all Patents, including the patents and patent applications set forth in Schedule A hereto (the “Patent Collateral”);

(ii) all Trademarks, including the trademark and service mark registrations and applications set forth in Schedule B hereto, together with the goodwill symbolized thereby (the “Trademark Collateral”);

(iii) all Copyrights, whether registered or unregistered, including, without limitation, the copyright registrations and applications set forth in Schedule C hereto (the “Copyright Collateral”);

(iv) all reissues, divisionals, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of the Grantor accruing thereunder or pertaining thereto;

(v) any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and

(vi) any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the foregoing of or arising from any of the foregoing.

Section 2. Security for Obligations. The grant of a security interest in the Collateral by the Grantor under this IP Security Agreement secures the payment of all Obligations (as such term is defined in the Note Purchase Agreement) of the Grantor now or hereafter existing under or in respect of the Loan Documents, whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations, interest, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise. Without limiting the generality of the foregoing, this IP Security Agreement secures, as to the Grantor, the payment of all amounts that constitute part of the Obligations that would be owed by the Grantor to the Noteholder under the Loan Documents but for the fact that they are unenforceable or not allowable due to the existence of a bankruptcy, or reorganization or similar proceeding involving the Grantor.

Section 3. Recordation. The Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for Trademarks record this IP Security Agreement.

Section 4. Execution in Counterparts; Electronic Signatures. This IP Security Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. This IP Security Agreement may be executed by electronic means (whether digital or encrypted) and the signatory of any such electronic signature shall intend for such electronic signature to have the full force and effect of a manual signature.

Section 5. Grants, Rights and Remedies. This IP Security Agreement has been entered into in conjunction with the provisions of the Loan Documents. Without limitation of the foregoing, this IP Security Agreement is expressly subject to the terms of Section 9 of the Security Agreement, and the security interest of the Noteholder in the Collateral granted hereunder shall terminate upon a Termination Event. The Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Noteholder with respect to the Collateral are more fully set forth in the Loan Documents, the terms and provisions of which are incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this IP Security Agreement and the terms of the Loan Documents, the terms of the Loan Documents shall govern.

Section 6. Governing Law; Venue; Waiver of Jury Trial.

(a) **THIS IP SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.**

(b) **THE PARTIES HERETO (A) HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMIT TO THE JURISDICTION OF THE STATE COURTS OF NEW YORK AND TO THE JURISDICTION OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK FOR THE PURPOSE OF ANY SUIT, ACTION OR OTHER PROCEEDING ARISING OUT OF OR BASED UPON THIS IP SECURITY AGREEMENT, (B) AGREE NOT TO COMMENCE ANY SUIT,**

ACTION OR OTHER PROCEEDING ARISING OUT OF OR BASED UPON THIS IP SECURITY AGREEMENT EXCEPT IN THE STATE COURTS OF NEW YORK OR THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK, AND (C) HEREBY WAIVE, AND AGREE NOT TO ASSERT, BY WAY OF MOTION, AS A DEFENSE, OR OTHERWISE, IN ANY SUCH SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT SUBJECT PERSONALLY TO THE JURISDICTION OF THE ABOVE-NAMED COURTS, THAT ITS PROPERTY IS EXEMPT OR IMMUNE FROM ATTACHMENT OR EXECUTION, THAT THE SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM, THAT THE VENUE OF THE SUIT, ACTION OR PROCEEDING IS IMPROPER OR THAT THIS IP SECURITY AGREEMENT OR THE SUBJECT MATTER HEREOF MAY NOT BE ENFORCED IN OR BY SUCH COURT.

(c) EACH PARTY HERETO HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS IP SECURITY AGREEMENT, THE OTHER DOCUMENTS REFERENCED HEREIN (INCLUDING, FOR THE AVOIDANCE OF DOUBT, THE LOAN DOCUMENTS) OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS IP SECURITY AGREEMENT, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

Section 7. Amendments and Waivers. Any term of this IP Security Agreement may be amended or waived only with the written consent of the Noteholder and the Grantor. Any amendment or waiver effected in accordance with this Section 7 shall be binding upon the parties hereto and each transferee of the Note, as applicable.

Section 8. Transfers; Successors and Assigns. The terms and conditions of this IP Security Agreement shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties hereto. Notwithstanding the foregoing, the Noteholder may not assign, pledge, or otherwise transfer this IP Security Agreement without the prior written consent of the Grantor, except for transfers to Affiliates, and the Grantor may not assign, pledge, or otherwise transfer this IP Security Agreement without the prior written consent of the Noteholder.

Section 9. Severability. If one or more provisions of this IP Security Agreement are held to be unenforceable under applicable law, the parties hereto agree to renegotiate such provision in good faith, in order to maintain the economic position enjoyed by each party as close as possible to that under the provision rendered unenforceable. In the event that the parties hereto cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this IP Security Agreement, (ii) the balance of this IP Security Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of this IP Security Agreement shall be enforceable in accordance with its terms.

Section 10. Entire Agreement. This IP Security Agreement, and the documents referred to herein (including, for the avoidance of doubt, the Loan Documents) constitute the entire agreement between the parties hereto pertaining to the subject matter hereof, and any and all other written or oral agreements existing between the parties hereto are expressly canceled.

Section 11. Specific Performance. It is hereby acknowledged and agreed that any breach of the covenants set forth in this IP Security Agreement would cause irreparable harm to the Noteholder, and that the Noteholder would not have any adequate remedy at law in the event that such covenants were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that, notwithstanding anything in this IP Security Agreement or the Loan Documents to the contrary, the Noteholder is entitled to seek equitable remedies in connection with any breach or breaches of the covenants set forth in this IP Security Agreement, and to enforce specifically the provisions of this IP Security Agreement in any federal or state courts located in the State of New York, this being in addition to any other remedy to which they are entitled at law or in equity.

[Signature Page Follows]

IN WITNESS WHEREOF, the Grantor and Noteholder have caused this IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first written above.

EPIC SCIENCES, INC.

DocuSigned by:
By: Lloyd Sanders
Name: Walter Lloyd Sanders
Title: President and Chief Executive Officer

**LABORATORY CORPORATION OF AMERICA
HOLDINGS**

By: _____
Name: Megann Vaughn Watters
Title: VP, Corporate Development

[Signature Page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the Grantor and Noteholder have caused this IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first written above.

EPIC SCIENCES, INC.

By: _____
Name:
Title:

**LABORATORY CORPORATION OF AMERICA
HOLDINGS**

By: Megann Vaughn Watters
Name: Megann Vaughn Watters
Title: VP, Corporate Development



Schedule A

United States Patents

[See attached.]

EPIC SCIENCES, INC.		United	0/3177-0026-488	2/8862/1/888/026					x		United States of America
EPIC SCIENCES, INC.		Not To Be Filed	0/3177-0026-488	2/8862/1/888/026					x		United States of America
EPIC 0/EPIC2		Equival	0/3177-0027-488	2/8862/1/888/027	6/164/146						United States of America
EPIC SCIENCES, INC.		United	0/3177-0028-888	2/8862/1/888/028					x		United States of America
EPIC 0/EPIC4, TSN Rd, 1408, 1/PT/ES0000P		Registered	0/3177-0029-401	2/8862/1/001/029	2/773/338						United States of America
EPIC SCIENCES, INC.		Registered	0/3177-0029-402	2/8862/1/002/029	1/08/96/36/4						United Kingdom
EPIC SCIENCES, INC.		Registered	0/3177-0029-403	2/8862/1/003/029	1/08/96/36/4						Germany
EPIC SCIENCES, INC.		Registered	0/3177-0029-404	2/8862/1/004/029	1/08/96/36/4						France
EPIC SCIENCES, INC.		Registered	0/3177-0029-405	2/8862/1/005/029	5/020/150/008/32/8						Italy
EPIC SCIENCES, INC.		Registered	0/3177-0029-407	2/8862/1/007/029	20/103/06/88						Australia
EPIC SCIENCES, INC.		Registered	0/3177-0029-412	2/8862/1/012/029	20/2/54/54/5						Japan
EPIC SCIENCES, INC.		Registered	0/3177-0029-413	2/8862/1/013/029	1/08/96/36/4						Switzerland
EPIC SCIENCES, INC.		Registered	0/3177-0029-418	2/8862/1/048/029	1/08/96/36/4						Netherlands
EPIC SCIENCES, INC.		Registered	0/3177-0029-454	2/8862/1/054/029	1/08/96/36/4						Spain
EPIC SCIENCES, INC.		Pending	0/3177-0029-146	2/8862/1/146/029	20/108/02/813/38						China
EPIC SCIENCES, INC.		EP Granted	0/3177-0029-227	2/8862/1/227/029	1/08/96/36/4						European Patent Office
EPIC SCIENCES, INC.		Equival	0/3177-0029-228		PC/US201/003/431						European Patent Office
EPIC SCIENCES, INC.		Equival	0/3177-0029-488	2/8862/1/888/029	6/163/187						United States of America
EPIC SCIENCES, INC.		Abandoned	0/3177-0029-469	2/8862/1/969/029	13/923/214						United States of America
EPIC SCIENCES, INC.		EP Granted	0/3177-0029-512	2/8862/1/012/030	2/08/54/28/13						Japan
EPIC SCIENCES, INC.		EP Granted	0/3177-0029-527	2/8862/1/227/030	07/06/46/8						European Patent Office
EPIC SCIENCES, INC.		Abandoned	0/3177-0029-999	2/8862/1/999/030	12/223/357						United States of America
EPIC SCIENCES, INC.		Abandoned	0/3177-0031-401	2/8862/1/001/031	2/736/178						China
EPIC SCIENCES, INC.		Abandoned	0/3177-0031-427	2/8862/1/270/31	0/68/12/27/1						European Patent Office
EPIC SCIENCES, INC.		Equival	0/3177-0031-228	2/8862/1/228/031	PC/US2020/004/5866						Patent Cooperation Treaty
EPIC SCIENCES, INC.		Registered	0/3177-0031-499	2/8862/1/999/031	12/953/123						United States of America
EPIC SCIENCES, INC.		Abandoned	0/3177-0032-999	2/8862/1/999/032	13/997/138						United States of America
EPIC SCIENCES, INC.		Abandoned	0/3177-0033-401	2/8862/1/001/033	2/772/823						China
EPIC SCIENCES, INC.		Abandoned	0/3177-0033-407	2/8862/1/007/033	20/108/94/6						Australia
EPIC SCIENCES, INC.		Pending	0/3177-0033-512	2/8862/1/012/033	20/2/54/54/5						Japan
EPIC SCIENCES, INC.		Abandoned	0/3177-0033-146	2/8862/1/146/033	20/108/03/91/714						China
EPIC SCIENCES, INC.		Equival	0/3177-0033-228	2/8862/1/228/033	PC/US2020/004/7876						Patent Cooperation Treaty
EPIC SCIENCES, INC.		Abandoned	0/3177-0033-549	2/8862/1/549/033	11/243/2177						United States of America
EPIC SCIENCES, INC.		Equival	0/3177-0033-528	2/8862/1/528/033	10/446/6/7						European Patent Office
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-401	2/8862/1/001/034	2/8862/1/001/034						China
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-407	2/8862/1/007/034	6/026/37						New Zealand
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-468	2/8862/1/068/034	16/020/14/008/84						Mexico
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-509	2/8862/1/009/034	16/020/14/008/84						Japan
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-512	2/8862/1/012/034	20/144/6/47						China
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-523	2/8862/1/023/034	15/122/51/5						Hong Kong
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-543	2/8862/1/043/034	11/244/03/117						Singapore
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-566	2/8862/1/066/034	51/18/CH/EP/2014						India
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-576	2/8862/1/076/034	P-40207104/110						Indonesia
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-146	2/8862/1/146/034	20/2/56/06/31/X						China
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-147	2/8862/1/147/034	20/104/04/68						South Africa
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-158	2/8862/1/158/034	23/53/07						Israel
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-187	2/8862/1/187/034	20/147/18/24						Republic of Korea
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-200	2/8862/1/200/034	20/147/14/10						European Patent Office
EPIC SCIENCES, INC.		Abandoned	0/3177-0034-227	2/8862/1/227/034	12/857/15/6						European Patent Office
EPIC SCIENCES, INC.		Equival	0/3177-0034-228	2/8862/1/228/034	PC/US2020/20/888/86						Patent Cooperation Treaty

[illegible]

[illegible]

EPIC SCIENCES, INC.	EPIC 020305	Regulated	0/3377-0065-999	23862/199062	6/071,1207			May-24-2022				METHODS FOR ANALYZING RARE CIRCULATING CELLS	United States of America
EPIC SCIENCES, INC.	EPIC Ref: EPIC 1591, T591 Ref: T591 Case 16.6, 1 EPIC020305P, Summary: 514-073	Abandoned	0/3377-0065-327	23862/273063	20/56054,4			Dec-11-2019				CIRCULATING TUMOR CELL DIAGNOSTICS FOR LUNG CANCER	European Patent Office
EPIC SCIENCES, INC.	1458, COA 31E02000P	Abandoned	0/3377-0064-999	23862/199064	16/618454			Mar-16-2020				METHOD OF USING NONHAPTIC CELLS TO DETECT RARE CELLS	United States of America
EPIC SCIENCES, INC.	EPIC Ref: EPIC 01805, T591 Ref: T591 Case 16.6, 1 US/E03073P	Abandoned	0/3377-0065-999	23862/199065	16/855,228			May-17-2020				CIRCULATING TUMOR CELL DIAGNOSTICS FOR LUNG CANCER	United States of America
EPIC SCIENCES, INC.	T591 Case 1599, 1 US / T591 0007P	Abandoned	0/3377-0065-999	23862/199066	16/864,377			May-17-2020				GENOMIC AND PHENOTYPIC ANALYSES OF CIRCULATING TUMOR CELLS TO MONITOR TUMOR EVOLUTION IN PROSTATE CANCER PATIENTS	United States of America
EPIC SCIENCES, INC.	EPIC 020305	Abandoned	0/3377-0067-999	23862/199067	16/862,232			Apr-13-2020				METHODS FOR DETECTION OF CIRCULATING TUMOR CELLS AND METHODS OF DIAGNOSIS OF CANCER IN A MAMMALIAN SUB-ECT	United States of America
EPIC SCIENCES, INC.	EPIC 0333AU	Abandoned	0/3377-0068-507	23862/1007068	2022/062064			Nov-01-2016				SINGLE CELL GENOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCs) IN METASTATIC DISEASE	Australia
EPIC SCIENCES, INC.		Pending	0/3377-0068-146	23862/1146468	2022/060619.2			Nov-01-2016				METHOD OF CHARACTERIZING DISEASE HETEROGENEITY	China
EPIC SCIENCES, INC.		Pending	0/3377-0068-999	23862/199068	17/621,171			Jun-06-2021				SINGLE CELL GENOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCs) IN METASTATIC DISEASE TO CHARACTERIZE DISEASE HETEROGENEITY	United States of America
EPIC SCIENCES, INC.	T591 Case 1672, COA 1E03039P	Abandoned	0/3377-0068-999	23862/199069	17/621,171			Jun-06-2021				COMPARISON AND METHODS FOR FLUID BIOPS OF METAPLASIA	United States of America
EPIC SCIENCES, INC.	EPIC 020305	Abandoned	0/3377-0070-999	23862/199070	17/642,662			Jun-06-2021				METHODS FOR THE DETECTION AND QUANTIFICATION OF CIRCULATING TUMOR CELL LINEAGES	United States of America
EPIC SCIENCES, INC.		Abandoned	0/3377-0071-999	23862/199071	17/710,109			Feb-05-2021				DETECTION OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION ON CIRCULATING TUMOR CELLS (CTCs) FROM URINE AND OF CIRCULATING TUMOR CELLS (CTCs) IN METASTATIC DISEASE	United States of America
EPIC SCIENCES, INC.		Final WIPO Exam	0/3377-0072-507	23862/1007072	2022/02282			Jun-05-2017				TO CHARACTERIZE DISEASE HETEROGENEITY	Australia
EPIC SCIENCES, INC.		Abandoned	0/3377-0072-012	23862/1012072	2021-054561			Jun-05-2017				SINGLE CELL GENOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCs) IN METASTATIC DISEASE	Japan
EPIC SCIENCES, INC.		Pending	0/3377-0072-146	23862/1146072	2022/060619.3			Jun-05-2017				METHOD OF CHARACTERIZING DISEASE HETEROGENEITY	China
EPIC SCIENCES, INC.		Pending	0/3377-0073-999	23862/199073	17/623,312			May-18-2021				CIRCULATING TUMOR CELL DIAGNOSTICS FOR IDENTIFICATION OF RESISTANCE TO ANDROGEN RECEPTOR TARGETED THERAPIES	United States of America
EPIC SCIENCES, INC.	EPIC 021052	Abandoned	0/3377-0074-999	23862/199074	17/623,376			May-18-2021				ANDROGEN RECEPTOR (AR) TARGETED THERAPIES FOR BIOMARKERS PREDICTIVE OF RESISTANCE TO ANDROGEN RECEPTOR (AR) TARGETED THERAPIES	United States of America
EPIC SCIENCES, INC.		Abandoned	0/3377-0075-999	23862/199075	17/627,231			Jun-15-2021				ANDROGEN RECEPTOR (AR) TARGETED THERAPIES FOR BIOMARKERS PREDICTIVE OF RESISTANCE TO ANDROGEN RECEPTOR (AR) TARGETED THERAPIES	United States of America
EPIC SCIENCES, INC.		Pending	0/3377-0076-999	23862/199076	17/628,346			Aug-10-2021				METHODS FOR THE DETECTION AND QUANTIFICATION OF CIRCULATING ENDOTHELIAL CELLS	United States of America
EPIC SCIENCES, INC.		Abandoned	0/3377-0077-012	23862/1012077	2022-060666			Jun-05-2017				SINGLE CELL GENOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCs) IN METASTATIC DISEASE TO DETECT DISEASE HETEROGENEITY	Japan
EPIC SCIENCES, INC.	EPIC 020305	Pending	0/3377-0077-999	23862/199077	17/612,437			Jun-18-2022				SINGLE CELL GENOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCs) IN METASTATIC DISEASE TO CHARACTERIZE DISEASE HETEROGENEITY	United States of America
EPIC SCIENCES, INC.	EPIC 020305	Pending	0/3377-0078-999	23862/199078	17/620,146			May-14-2022				CIRCULATING TUMOR CELL DIAGNOSTICS FOR DETECTION OF NEUROENDOCRINE PROSTATE CANCER (NEPC)	United States of America
EPIC SCIENCES, INC.	1458, COA 1E03009P	Pending	0/3377-0079-999	23862/199079	17/646,156			May-14-2022				METHOD OF USING NONHAPTIC CELLS TO DETECT RARE CELLS	United States of America
EPIC SCIENCES, INC.	EPIC Ref: EPIC 01805, T591 Ref: T591 Case 16.6, 1 COA 1E030100P	Pending	0/3377-0080-999	23862/199080	18/045,159			Oct-14-2022				CIRCULATING TUMOR CELL DIAGNOSTICS FOR LUNG CANCER	United States of America
EPIC SCIENCES, INC.		Final WIPO Exam	0/3377-0081-146	23862/1146081	2022/06251097.9			Sep-15-2016				ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC PROSTATE CANCER	China
EPIC SCIENCES, INC.	EPIC 020305	Pending	0/3377-0081-999	23862/199081	18/175,427			Feb-27-2023				ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC PROSTATE CANCER (MPCP)	United States of America
EPIC SCIENCES, INC.	T591 Case 1599, 1 US / E030087P	Pending	0/3377-0082-999	23862/199082	18/174,015			Feb-24-2023				EVOLUTIONARY AND PHENOTYPIC ANALYSES OF CIRCULATING TUMOR CELLS TO MONITOR TUMOR EVOLUTION IN PROSTATE CANCER PATIENTS	United States of America
EPIC SCIENCES, INC.	EPIC 020305	Pending	0/3377-0083-999	23862/199083	18/035,379			Apr-27-2023				EVOLUTIONARY AND PHENOTYPIC ANALYSES OF CIRCULATING TUMOR CELLS TO MONITOR TUMOR EVOLUTION IN PROSTATE CANCER PATIENTS	United States of America
EPIC SCIENCES, INC.		Abandoned	0/3377-0084-012	23862/1012084	2022-060666			Jun-01-2018				METHODS OF DETERMINING THERAPIES BASED ON CELL CHARACTERIZATION OF CIRCULATING TUMOR CELLS (CTCs) IN METASTATIC DISEASE	Japan
EPIC SCIENCES, INC.	EPIC 021052	Pending	0/3377-0085-999	23862/199085	19/045,255			Oct-06-2023				CIRCULATING TUMOR CELL DIAGNOSTICS FOR BIOMARKERS PREDICTIVE OF RESISTANCE TO ANDROGEN RECEPTOR (AR) TARGETED THERAPIES	United States of America
EPIC SCIENCES, INC.	T591 Case 1672, COA 1E030170P	Abandoned	0/3377-0086-999	23862/199086	18/066,314			Mar-05-2024				COMPARISON AND METHODS FOR FLUID BIOPSY OF METAPLASIA	United States of America
EPIC SCIENCES, INC.		Final WIPO Exam	0/3377-0087-146	23862/1146087	2022/06251031.0			Sep-15-2016				ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC PROSTATE CANCER (MPCP)	China
EPIC SCIENCES, INC.	EPIC 020305	Pending	0/3377-0088-999	23862/199088	18/616,257			May-16-2024				METHODS FOR THE DETECTION AND QUANTIFICATION OF CIRCULATING TUMOR CELL LINEAGES	United States of America
EPIC SCIENCES, INC.		Unfiled	0/3377-0088-999									METHODS OF DETERMINING THERAPIES BASED ON SINGLE CELL CHARACTERIZATION OF CIRCULATING TUMOR CELLS (CTCs) IN METASTATIC DISEASE	United States of America

Status	Official No.	Appln. No.	Appln Date	Pub. Date	Pub. No.	Title	Reg. No.	Reg. Date	Country
Pending		PCT/US2022/052147	Dec. 7, 2022	June 15, 2023	WO2023/107566	ENHANCED CHARACTERIZATION OF BREAST CANCER			PCT
Pending		18/076,945	Dec. 7, 2022	June 8, 2023	US2023/017507/3B	ENHANCED CHARACTERIZATION OF BREAST CANCER			U.S.

Status	Official No.	Appln. No.	Appln Date	Pub. Date	Pub. No.	Title	Reg. No.	Reg. Date	Country
Expired	WO2016/172160 A1	PCT/US2016/028372	April 20, 2016	Oct. 27, 2016	WO2016/172160 A1	COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS			PCT
			April 20, 2016	Feb. 28, 2018	EP3286565 A1	COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS			Europe
Registered		CN 108064343 A	April 20, 2016	May 22, 2018	CN108064343 B	COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS	CN108064343 B	July, 9, 2021	China
		CN113552350 A	April 20, 2016	Oct. 26, 2021		COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS			China
Registered		JP2018517129	April 20, 2016	June 28, 2018	JP6815331 B3	COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS	JP6815331 B3	Jan. 20, 2021	Japan
Registered			Dec. 22, 2020	Feb. 17, 2022	JP7022191 B2	COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS	JP7022191 B2	Feb. 17, 2022	Japan
Registered		HK1255484A	July 26, 2018	Nov. 16, 2018	HK1255484B	COMPOSITIONS AND METHODS FOR PROSTATE	HK1255484B		Hong Kong

Status	Official No.	Appln. No.	Appln Date	Pub. Date	Pub. No.	Title	Reg. No.	Reg. Date	Country
ABN		US15/789,768	Oct. 20, 2017	July 26, 2018	US2018/0209282A1	CANCER ANALYSIS			U.S.
Registered		US16/721,108	Dec., 19, 2019	June 26, 2020	US20200200752A1	COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS			U.S.
Expired		PCT/IB2013/050547	Jan. 22, 2013	Aug., 1, 2013	WO2013/111054	METHODS FOR DETECTING 5T4-POSITIVE CIRCULATING TUMOR CELLS AND METHODS OF DIAGNOSIS OF 5T4- POSITIVE CANCER IN A MAMMALIAN SUBJECT			PCT
ABN		AU2013213301A1	Jan. 22, 2013	July 17, 2014	AU2013213301A1	SAME AS ABOVE			
		BR112014018192A	Jan. 22, 2013	Mar. 2, 2021	BR112014018192AB	SAME AS ABOVE			Brazil
Expired (fee related)		CA2861437A	Jan. 22, 2013	Aug. 1, 2013	CA2861437C	SAME AS ABOVE	CA2861437C	Aug. 21, 2018	Canada
Expired (fee related)		CN201380006333.9A	Jan. 22, 2013	Oct. 8, 2014	CN104094116B	SAME AS ABOVE	CN104094116B	May 31, 2017	China
Active		EP13708526.2A	Jan. 22, 2013	Dec. 3, 2014	EP2807485B1	SAME AS ABOVE	EP2807485B1	March 13, 2019	Europe
		HK1202923A1	Apr 8, 2015	Oct 9, 2015		SAME AS ABOVE			Hong Kong
		IL233543A	July 7, 2014	Feb. 28, 2018	IL233543B	SAME AS ABOVE			Israel
		IN2014DN07019A	Jan. 22, 2013	Apr. 10, 2015	IN2014DN07019B	SAME AS ABOVE			India
Registered		KR1020147020394A	Jan. 22, 2013	Aug. 14, 2014	KR101716555B1		KR101716555B1	Mar. 14, 2017	Korea
		MX2014008928A	Jan. 22, 2013	Nov. 23, 2018	MX361058B				Mexico

Status	Official No.	Appln. No.	Appln Date	Pub. Date	Pub. No.	Title	Reg. No.	Reg. Date	Country
Registered		RU2014127474A	Jan. 22, 2013	Mar. 20, 2016	RU2646498C		RU2646498C	Mar. 5, 2018	Russia
Expired (fee related)		US14/374,083		Jan. 15, 2015	US2015/001766		10,254,286 B2	Apr. 9, 2019	U.S.

Schedule B

Trademarks

<u>Company</u>	<u>Trademark</u>	<u>Registration No. / Application No.</u>	<u>Registration Date</u>	<u>Jurisdiction</u>
Epic Sciences, Inc.	“The Power of Clarity”	U.S. Registration #88296362	August 11, 2020	United States
Epic Sciences, Inc.	stylized lowercase “e”	U.S. Registration #88296351	October 06, 2020	United States
Epic Sciences, Inc.	“No Cell Left Behind”	U.S. Registration #86976496	August 04, 2015	United States

Schedule C

Copyrights

None.